The difference between aximinib and orebatinib

Although Asciminib and Olverembatinib are both targeted drugs in the treatment of chronic myeloid leukemia (CML), they have significant differences in many aspects such as research and development background, drug characteristics, treatment scope and efficacy.

R&D background and drug characteristics

Asciminib (Asciminib): Developed by Novartis and approved by the U.S. Food and Drug Administration (FDA) in 2021, it is a STAMP inhibitor that specifically targets the myristoyl pocket (STAMP) of the BCR-ABL1 protein and can lock BCR-ABL1 into an inactive conformation.

Olverembatinib (Olverembatinib): Developed by a local Chinese pharmaceutical company, it is my country’s first third-generation BCR-ABL inhibitor with independent intellectual property rights. It has strong and durable efficacy against BCR-Abl tyrosine kinase wild type and multiple mutants.

Treatment scope and efficacy

Asiminib: Mainly used to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP) who have previously received at least two tyrosine kinase inhibitors (TKIs). Clinical data showed that in the ASCEMBL trial, asiminib almost doubled the major molecular response (MMR) rate at week 24 compared with bosutinib (25% vs. 13%).

Orebatinib: Not only suitable for patients in the chronic phaseCML, but also in patients in the accelerated phase. In addition, orebatinib has strong and durable efficacy in CML patients with T315I mutation. The drug has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2022)", and its efficacy and safety have been recognized by the international hematology community.

Aximinib and orebatinib have their own characteristics in the treatment of chronic myeloid leukemia. As a STAMP inhibitor, aximinib has a unique mechanism of action; while orebatinib, as a domestic innovative drug, has demonstrated its unique advantages in treatment scope and efficacy. Patients should choose appropriate drugs for treatment based on their own condition and doctor's recommendations.